30-day DAPT + Guideline-directed therapy
ApprovedRecruiting 3 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndrome
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI, Bleeding, Stroke, Stent Thrombosis, Embolism, Coronary Artery Disease
Trial Timeline
Jan 11, 2023 → Dec 1, 2027
NCT ID
NCT04436978About 30-day DAPT + Guideline-directed therapy
30-day DAPT + Guideline-directed therapy is a approved stage product being developed by Daiichi Sankyo for Acute Coronary Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04436978. Target conditions include Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation.
What happened to similar drugs?
20 of 20 similar drugs in Acute Coronary Syndrome were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04436978 | Approved | Recruiting |
Competing Products
20 competing products in Acute Coronary Syndrome